ArticleCurrent microbiology2025
Paraprobiotics Mitigate Inflammation and Anxiety-Like Behavior in a Lipopolysaccharide-Induced Mouse Model.
Article in Current microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Healthy Nutrition and Fermented Animal-Sourced Foods as a Complementary One Health Strategy: Effects on Foodborne Pathogens and Intestinal Host Defense.Journal of clinical practice and research · 2026Review
- Dietary semen cuscuta improves laying performance by stabilizing mitochondria-associated membranes (MAMs) and inhibiting granulosa cell apoptosis in laying hens.Poultry science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluated the effects of supplementing five different paraprobiotics on anxiety-like behavior, intestinal health, anti-inflammatory activity, and oxidative and nitrosative stress in an animal model of acute inflammation. Male adult Balb/C mice were divided into twelve groups and received either saline solution or paraprobiotic supplements daily for 15 days at a concentration of 100 mg/animal/day. Following the supplementation period, some groups were administered an inflammatory insult with lipopolysaccharide (LPS) at a dose of 15 mg/kg. After 24 h of LPS administration, the groups supplemented with B. lactis, S. thermophilus, and L. casei showed improved anxiety-like behavior compared to the LPS group. Serum interleukin IL-1β levels were reduced in all paraprobiotic-supplemented groups post-inflammation, with IL-6 levels specifically reduced by L. casei. IL-10 levels remained unchanged. In the gut, certain paraprobiotics mitigated cytokine alterations induced by LPS. Myeloperoxidase activity, elevated by LPS, was blocked by paraprobiotic supplementation in the blood, intestine, and brain. All paraprobiotic-supplemented groups exhibited significant reductions in nitrite/nitrate levels across various organs following LPS insult. No oxidative damage related to lipid peroxidation was observed in any group. Histological analysis revealed that LPS-induced intestinal damage was prevented in paraprobiotic-supplemented animals, as indicated by well-developed villi, intact brush borders, and absence of necrosis. Paraprobiotic supplementation modulated the inflammatory response, enhanced intestinal integrity and barrier function, and improved anxiety-like behavior in the mouse model of acute inflammation.
Indexed as
Identifiers
40663206What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.